AR127247A1 - Inhibidores de cdk2 de ciclopentilpirazol - Google Patents
Inhibidores de cdk2 de ciclopentilpirazolInfo
- Publication number
- AR127247A1 AR127247A1 ARP220102682A ARP220102682A AR127247A1 AR 127247 A1 AR127247 A1 AR 127247A1 AR P220102682 A ARP220102682 A AR P220102682A AR P220102682 A ARP220102682 A AR P220102682A AR 127247 A1 AR127247 A1 AR 127247A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- subject
- pharmaceutical composition
- cdk2
- acceptable salt
- Prior art date
Links
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 title abstract 3
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 title abstract 3
- DTJJREHRTQMDJV-UHFFFAOYSA-N 5-cyclopentyl-1h-pyrazole Chemical compound C1CCCC1C1=NNC=C1 DTJJREHRTQMDJV-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente se describen compuestos de fórmula (1) y sales farmacéuticamente aceptables de estos, composiciones farmacéuticas que los comprenden, y sus usos y preparación. Reivindicación 70: Una composición farmacéutica que comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este, y un excipiente farmacéuticamente aceptable. Reivindicación 71: Un método para tratar un trastorno mediado por CDK2 en un sujeto que lo necesita, en donde el método comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este, o una composición farmacéutica de acuerdo con la reivindicación 70. Reivindicación 74: Un método para elaborar un medicamento para tratar un trastorno mediado por CDK2 en un sujeto que lo necesita, caracterizado porque se usa el compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este, o una composición farmacéutica de acuerdo con la reivindicación 70.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252394P | 2021-10-05 | 2021-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127247A1 true AR127247A1 (es) | 2024-01-03 |
Family
ID=84245758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102682A AR127247A1 (es) | 2021-10-05 | 2022-10-04 | Inhibidores de cdk2 de ciclopentilpirazol |
Country Status (7)
| Country | Link |
|---|---|
| KR (1) | KR20240077491A (es) |
| CN (1) | CN118019734A (es) |
| AR (1) | AR127247A1 (es) |
| AU (1) | AU2022360968A1 (es) |
| CA (1) | CA3229067A1 (es) |
| TW (1) | TW202330501A (es) |
| WO (1) | WO2023060057A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023208143A1 (zh) * | 2022-04-28 | 2023-11-02 | 正大天晴药业集团股份有限公司 | 一种吡唑取代环戊酯衍生物及其用途 |
| WO2024104455A1 (zh) * | 2022-11-17 | 2024-05-23 | 山东绿叶制药有限公司 | Cdk2抑制剂及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021009276A (es) * | 2019-01-31 | 2021-08-24 | Pfizer | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2. |
| CN110536068B (zh) | 2019-09-29 | 2021-09-28 | Oppo广东移动通信有限公司 | 对焦方法和装置、电子设备、计算机可读存储介质 |
| KR20230173083A (ko) * | 2021-02-12 | 2023-12-26 | 릴레이 테라퓨틱스, 인크. | Cdk 억제제 및 이의 사용 방법 |
-
2022
- 2022-10-04 WO PCT/US2022/077501 patent/WO2023060057A1/en active Application Filing
- 2022-10-04 CN CN202280065852.1A patent/CN118019734A/zh active Pending
- 2022-10-04 AR ARP220102682A patent/AR127247A1/es unknown
- 2022-10-04 AU AU2022360968A patent/AU2022360968A1/en active Pending
- 2022-10-04 TW TW111137712A patent/TW202330501A/zh unknown
- 2022-10-04 CA CA3229067A patent/CA3229067A1/en active Pending
- 2022-10-04 KR KR1020247011084A patent/KR20240077491A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022360968A1 (en) | 2024-02-29 |
| CN118019734A (zh) | 2024-05-10 |
| TW202330501A (zh) | 2023-08-01 |
| KR20240077491A (ko) | 2024-05-31 |
| CA3229067A1 (en) | 2023-04-13 |
| WO2023060057A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023000199A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| CL2023001476A1 (es) | Nuevos agentes antivirales derivados de la espiropirrolidina | |
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| CO2023002852A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| ECSP23095674A (es) | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| AR127501A1 (es) | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos | |
| AR128717A1 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| AR111464A1 (es) | Terapia combinada para el tratamiento de infecciones virales | |
| DOP2021000254A (es) | Compuestos de pirrolidina | |
| AR125798A1 (es) | Degradadores cdk2 y usos de los mismos | |
| CO4130200A1 (es) | Inhibidores de proteasa del hiv utiles en el tratamiento del sida | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| AR128257A1 (es) | Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting | |
| AR127561A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| BR112022016124A2 (pt) | Composto de di-hidronaftiridinona, e método de preparação para este e uso médico deste | |
| AR126482A1 (es) | Agentes antivirales derivados de espiropirrolidina | |
| AR126835A1 (es) | Análogos deuterados y derivados de 4-bromo-2,5-dimetoxifenetilamina y usos de estos |